Iron Deficiency Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others), By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

Global Iron Deficiency Anemia Market was valued at USD 5.14 Billion in 2024 and is expected to reach USD 7.59 Billion in the forecast period with a CAGR of 6.68% through 2030. The global iron deficiency anemia market is a complex and dynamic sector within the broader healthcare industry, characterized by a significant prevalence of iron deficiency anemia (IDA) worldwide. This condition, which results from a shortage of iron in the body, remains a major public health concern due to its widespread occurrence, affecting individuals of all age groups and demographics. The market encompasses a range of diagnostic tools, therapeutic interventions, and supportive care measures aimed at addressing the multifaceted challenges posed by IDA. One of the key drivers of the global iron deficiency anemia market is the growing awareness of the condition and its consequences. As healthcare systems become more sophisticated and accessible, more individuals are being screened and diagnosed with IDA, leading to increased demand for treatment options. This has prompted pharmaceutical companies and healthcare providers to invest in research and development to create innovative therapies and diagnostic solutions.

The market for iron deficiency anemia is also influenced by factors such as the rising global population, changing dietary habits, and an aging demographic. These factors contribute to the increasing prevalence of IDA and the subsequent need for effective treatment and management strategies. Additionally, emerging economies with improving healthcare infrastructure are witnessing a surge in demand for IDA-related products and services. In terms of product offerings, the global iron deficiency anemia market includes iron supplements, blood transfusions, and erythropoiesis-stimulating agents, among others. Iron supplementation remains the cornerstone of IDA management, with various formulations available to cater to patient preferences and tolerances. Blood transfusions are typically reserved for severe cases, while erythropoiesis-stimulating agents may be employed in select situations to boost red blood cell production.

Key Market Drivers

Rising Prevalence of Iron Deficiency Anemia

​The rising prevalence of iron deficiency anemia (IDA) is undeniably a major driving force behind the growth of the global iron deficiency anemia market. IDA has emerged as a widespread and pervasive health issue, affecting people of all ages and backgrounds worldwide. Several factors contribute to the increasing prevalence of this condition, making it a significant market driver.​

Firstly, shifts in dietary patterns have played a pivotal role. Modern lifestyles often favor diets that are low in iron-rich foods, such as red meat and leafy greens, and high in processed foods that may lack essential nutrients. Vegetarian and vegan diets, which have gained popularity for ethical and environmental reasons, can also be deficient in heme iron, further exacerbating the problem. These dietary trends have led to an increased risk of iron deficiency, propelling the demand for iron supplementation, fortified foods, and related products.​

Secondly, various health conditions and chronic diseases contribute to the prevalence of IDA. Gastrointestinal disorders, such as celiac disease and inflammatory bowel disease, can impair iron absorption, making individuals more susceptible to anemia. Moreover, chronic inflammatory conditions can lead to the sequestration of iron within cells, reducing its availability for red blood cell production. As these conditions become more prevalent, the need for effective iron deficiency anemia management and treatment options grows.​

Thirdly, the global aging population is a critical factor in the increasing prevalence of IDA. Elderly individuals are more prone to anemia due to factors like reduced iron absorption, chronic medical conditions, and the use of medications that may interfere with iron metabolism. As the proportion of older adults continues to rise, healthcare systems face a growing challenge in addressing the unique needs of this demographic, thereby driving the demand for iron deficiency anemia-related care and solutions.​

Gender-specific factors, such as menstrual blood loss in women and the increased iron requirements during pregnancy, contribute significantly to the prevalence of IDA. Women of childbearing age are particularly susceptible to iron deficiency anemia, emphasizing the importance of addressing this issue in reproductive healthcare.​

According to the World Health Organization (WHO), in 2019, the global prevalence of anemia was 29.9% among women of reproductive age, equating to over half a billion women aged 15-49 years. For children aged 6-59 months, the prevalence was 39.8%, affecting approximately 269 million children. ​

In India, anemia remains a significant public health concern. The National Family Health Survey (NFHS-5) conducted in 2019-2021 reported that 57.0% of women aged 15-49 years and 67.1% of children aged 6-59 months were anemic. These statistics highlight the urgent need for effective interventions to combat iron deficiency anemia in the country.​ These statistics underscore the widespread nature of iron deficiency anemia and the pressing need for effective interventions to address this global health challenge.

Advancements in Diagnostic Technologies

Advancements in diagnostic technologies have emerged as a crucial driver propelling the growth of the global iron deficiency anemia (IDA) market. Accurate and timely diagnosis is essential for effective management of this prevalent condition, and innovative diagnostic tools have significantly improved healthcare professionals' ability to identify and address IDA. Several key factors highlight the pivotal role of these technological advancements in driving market growth.

Firstly, the development of more sensitive and specific diagnostic tests has enhanced the precision of IDA diagnosis. Traditional methods like hemoglobin and serum ferritin level measurements are still valuable but have been supplemented with sophisticated laboratory techniques, such as bone marrow aspiration and iron studies. These tests allow healthcare providers to not only diagnose IDA but also determine its underlying causes, facilitating more targeted treatment strategies.

Secondly, point-of-care testing (POCT) devices and home-based test kits have democratized IDA diagnosis, making it more accessible to patients and reducing the burden on healthcare systems. POCT devices provide rapid results, allowing for immediate intervention, while home-based kits empower individuals to monitor their iron status regularly. These advancements promote early detection and treatment, contributing to improved patient outcomes.

Furthermore, the integration of digital health technologies and electronic health records (EHRs) has streamlined the diagnostic process. Healthcare providers can now access patients' historical data, track trends in iron levels, and make more informed decisions regarding treatment plans. Additionally, telemedicine platforms enable remote consultations and monitoring, facilitating timely interventions for individuals with IDA, especially those in underserved or remote areas.

Recent statistics underscore the significance of these advancements. According to the National Health and Nutrition Examination Survey (NHANES) conducted between August 2021 and August 2023, the prevalence of anemia in the U.S. population aged 2 years and older was 9.3%, with higher rates observed in females (13.0%) compared to males (5.5%). Notably, the prevalence was highest among Black non-Hispanic individuals (22.0%), highlighting disparities that advanced diagnostic tools can help address through earlier detection and targeted interventions. ​

Globally, the World Health Organization (WHO) estimates that anemia affects 40% of children aged 6–59 months, 37% of pregnant women, and 30% of women aged 15–49 years. These figures emphasize the widespread nature of IDA and the critical need for advanced diagnostic technologies to facilitate early detection and management, ultimately reducing the global burden of the disease.​

In England, hospital admissions due to iron deficiency have seen a substantial rise. In the 2023-24 period, there were 191,927 admissions where the primary reason was a lack of iron, marking an 11% increase from the previous year and nearly a tenfold rise compared to 1998-99. This surge underscores the pressing need for advanced diagnostic technologies to enable early detection and reduce hospital admissions related to IDA.​ Collectively, these advancements in diagnostic technologies not only enhance the accuracy and accessibility of IDA diagnosis but also contribute significantly to the growth of the global IDA market. By facilitating early detection and personalized treatment strategies, these innovations play a crucial role in improving patient outcomes and addressing the global burden of iron deficiency anemia.

Increasing Awareness and Education

The global iron deficiency anemia (IDA) market has experienced significant growth due to the increasing awareness and education surrounding this widespread health condition. Awareness campaigns and educational initiatives have played a pivotal role in boosting both the recognition of IDA as a public health concern and the demand for diagnostic tools and treatments. Several key factors underscore the profound impact of heightened awareness and education on the IDA market. healthcare organizations, government agencies, and non-profit organizations have been instrumental in raising awareness about IDA. They have conducted campaigns targeting both healthcare professionals and the general population, emphasizing the importance of early detection and management of IDA. These efforts have led to a greater number of individuals seeking medical attention for symptoms like fatigue and weakness, resulting in increased diagnoses and treatment initiation.

Patient education initiatives have empowered individuals to recognize the signs and risk factors associated with IDA. Patients are now more informed about the dietary choices, lifestyle habits, and health conditions that may predispose them to iron deficiency. This knowledge has encouraged proactive behavior, including seeking medical advice and adhering to recommended treatment plans, ultimately contributing to improved patient outcomes. Furthermore, the dissemination of information through various media channels, including the internet and social media, has made IDA-related knowledge more accessible to a broader audience. Patients and their families can easily access reputable sources of information, enabling them to make informed decisions about their healthcare. Additionally, online communities and support groups have emerged, fostering a sense of solidarity among individuals living with IDA and providing a platform for sharing experiences and advice. Incorporating IDA education into medical curricula and continuing education programs for healthcare professionals has also been pivotal. Physicians, nurses, and other healthcare providers are now better equipped to recognize and manage IDA, leading to more accurate diagnoses and tailored treatment plans for patients.

Download Free Sample Report

Key Market Challenges

Economic Disparities and Access to Care

Iron deficiency anemia (IDA) is a global health concern affecting millions of individuals, but its impact is disproportionately felt among those facing economic disparities and limited access to healthcare. Economic disparities and unequal access to care are significant challenges that hinder the progress of the global IDA market. In low-income and developing countries, where economic disparities are more pronounced, access to basic healthcare services can be severely limited. Many individuals in these regions do not have access to regular healthcare check-ups or affordable diagnostic tests. As a result, cases of IDA often go undiagnosed or are diagnosed at later stages, when the condition has already become severe.

Even when individuals are aware of their IDA symptoms, they may not have the financial means to seek medical attention. The cost of healthcare services, including doctor visits, laboratory tests, and prescribed medications, can be prohibitively high for those living in poverty. This economic barrier not only prevents timely diagnosis but also hinders access to necessary treatments. Furthermore, the availability of iron supplementation, a key component of IDA management, can be inconsistent in resource-constrained settings. Iron supplements may be expensive or simply unavailable, particularly in rural or underserved areas. As a result, individuals with IDA continue to suffer the consequences of their condition, such as fatigue and decreased quality of life. Pregnant women, infants, and children are particularly vulnerable to the effects of economic disparities and limited access to care. IDA can have serious consequences during pregnancy and early childhood, leading to complications like preterm birth and developmental delays. However, these at-risk populations often face barriers to receiving appropriate care due to their economic circumstances.

Misdiagnosis and Underdiagnosis

Iron deficiency anemia (IDA) is a common and often underestimated health condition that affects millions of people worldwide. However, the accurate diagnosis of IDA remains a significant challenge, leading to both misdiagnosis and underdiagnosis. These diagnostic hurdles hinder the growth and effectiveness of the global IDA market. Misdiagnosis occurs when healthcare providers incorrectly identify the cause of a patient's symptoms, attributing them to other medical conditions instead of IDA. The symptoms of IDA, such as fatigue, weakness, and pallor, can overlap with those of various other health issues, including chronic diseases and infections. Consequently, healthcare professionals may focus on treating the underlying condition rather than investigating the possibility of IDA. This delay in accurate diagnosis can lead to prolonged suffering for patients and ineffective treatment, thereby hindering the market's progress.

On the other hand, underdiagnosis involves a failure to recognize IDA when a patient exhibits symptoms indicative of the condition. Some individuals may experience mild or nonspecific symptoms that are not immediately associated with anemia, leading to overlooked cases. Furthermore, routine health check-ups and screenings do not always include comprehensive assessments for IDA, which can result in missed opportunities for diagnosis, particularly in asymptomatic or subclinical cases.

Key Market Trends

Treatment Innovation and Diversification

Treatment innovation and diversification have emerged as crucial drivers in boosting the global iron deficiency anemia (IDA) market. Traditionally, IDA management relied heavily on iron supplementation, but recent innovations have expanded the therapeutic options available to healthcare providers and patients, driving the growth of the market. Iron supplementation, in various forms such as oral tablets, liquid solutions, and intravenous preparations, remains a cornerstone of IDA treatment. However, innovation in this area has led to improved formulations with enhanced bioavailability and reduced side effects. These advancements address patient concerns regarding treatment tolerability and adherence, ultimately improving treatment outcomes.

Furthermore, erythropoiesis-stimulating agents (ESAs) have revolutionized the approach to IDA treatment. ESAs stimulate the production of red blood cells in the bone marrow, reducing the need for blood transfusions, which were traditionally reserved for severe IDA cases. This innovation not only minimizes the risks associated with transfusions but also offers a more convenient and patient-friendly treatment option, contributing to the market's expansion.Additionally, treatment diversification has led to the development of targeted therapies aimed at addressing the specific underlying causes of IDA. For instance, individuals with gastrointestinal disorders that impair iron absorption now have access to therapies designed to improve iron utilization in the gut. These tailored approaches provide more effective and personalized treatment strategies, ensuring that the root causes of IDA are adequately addressed. Combining these treatment innovations with ongoing research into novel therapies, pharmaceutical companies and healthcare providers are creating a more comprehensive and effective ecosystem for managing IDA. This diversification not only improves patient outcomes but also broadens the market's reach by catering to the unique needs and preferences of a diverse patient population.

Nutritional Fortification and Dietary Awareness

Nutritional fortification and dietary awareness are playing a significant role in boosting the global iron deficiency anemia (IDA) market. As awareness about IDA and its risk factors spreads, more attention is being given to dietary habits and nutritional strategies to prevent and manage this condition. Manufacturers are increasingly fortifying a wide range of foods and beverages with iron, making it easier for individuals to meet their daily iron requirements. Staple foods like rice, flour, and breakfast cereals are often fortified with iron, ensuring that even those with limited access to diverse diets can obtain essential nutrients. This fortification not only aids in preventing IDA but also contributes to the treatment of mild cases.

Dietary awareness campaigns and educational initiatives have emphasized the importance of consuming iron-rich foods as part of a balanced diet. Leafy greens, red meat, beans, nuts, and fortified grains are being promoted as dietary sources of iron. These initiatives empower individuals to make informed dietary choices that can help prevent IDA and improve their overall health. Furthermore, nutritional fortification and dietary awareness have a significant impact on vulnerable populations, such as pregnant women, infants, and young children. Iron requirements are particularly high during pregnancy and early childhood, making nutritional interventions critical for these age groups. Fortified prenatal supplements and infant formula, combined with dietary education for mothers, help ensure adequate iron intake for both the mother and the developing fetus.

Segmental Insights

Therapy Areas Insights

Based on the Therapy Areas, Obstetrics and Gynecology emerged as the dominant segment in the Global Iron Deficiency Anemia Market in 2024. This is due to the high prevalence of anemia among women, particularly during pregnancy and postpartum periods. According to the World Health Organization (WHO), approximately 37% of pregnant women and 30% of women of reproductive age worldwide suffer from anemia, with iron deficiency being the primary cause. During pregnancy, the body’s demand for iron increases significantly to support fetal growth and increased blood volume, making pregnant women particularly vulnerable to IDA. Left untreated, IDA in pregnancy can lead to complications such as preterm birth, low birth weight, and maternal morbidity. As a result, governments and healthcare organizations have intensified efforts to improve screening, supplementation, and treatment for IDA in obstetric care. Additionally, conditions such as heavy menstrual bleeding (menorrhagia) further contribute to the high burden of IDA in gynecological settings. With growing awareness and the introduction of novel oral and intravenous iron formulations, treatment accessibility has improved, driving market growth in this segment.

End User Insights

Based on the End User, Hospitals & Clinics emerged as the dominant segment in the Global Iron Deficiency Anemia Market in 2024. This is driven by several key factors. These healthcare facilities serve as primary centers for diagnosis, treatment, and management of IDA, offering specialized care, advanced diagnostic tools, and a wide range of treatment options, including intravenous (IV) iron therapies. The increasing prevalence of IDA, particularly among women, children, and patients with chronic diseases, has led to a higher influx of patients in hospitals and clinics. These facilities provide comprehensive care, from initial diagnosis through complete blood count (CBC) tests and ferritin level assessments to advanced treatments like blood transfusions and iron infusions, which are often required for severe cases.

Regional Insights

North America emerged as the dominant region in the Global Iron Deficiency Anemia Market in 2024. This is driven by advanced healthcare infrastructure, high awareness levels, and the widespread availability of innovative diagnostic and treatment options. The region benefits from a strong presence of leading pharmaceutical companies investing in novel therapies, including intravenous iron formulations and oral iron supplements, to address iron deficiency effectively. The rising prevalence of anemia, particularly among women, children, and the elderly, has fueled market growth. According to the Centers for Disease Control and Prevention (CDC), anemia affects approximately 9.3% of the U.S. population, with significantly higher rates in specific demographics. Additionally, the growing burden of chronic diseases such as chronic kidney disease (CKD) and inflammatory bowel disease (IBD), which are often associated with anemia, has increased the demand for effective management solutions.

Asia-Pacific emerged as the fastest growing region in the Global Iron Deficiency Anemia Market during the forecast period. This is driven by a rising prevalence of anemia, especially among women and children. According to the World Health Organization (WHO), anemia affects approximately 40% of children and 30% of women of reproductive age in the region, highlighting a significant healthcare burden. The high incidence of malnutrition, inadequate dietary iron intake, and parasitic infections such as hookworm further contribute to the increasing demand for effective anemia management solutions. Governments across Asia-Pacific have recognized this challenge and launched large-scale initiatives to combat iron deficiency, such as India’s Anemia Mukt Bharat program and China’s national nutrition improvement plans. These programs focus on iron supplementation, fortification of staple foods, and public health awareness campaigns, significantly boosting the demand for iron-based therapies. Additionally, the growing population and rising healthcare expenditure in countries like India, China, and Indonesia are driving investments in the development and distribution of novel diagnostic tools and treatment options, further accelerating market growth.

• In September 2024, Zuventus Healthcare received approval from the CDSCO's Subject Expert Committee (SEC) to manufacture and market Ferrous Ascorbate suspension (30 mg/5 ml) for iron deficiency anaemia. The approval was granted with a waiver for clinical trials and bioequivalence studies after the company presented safety and efficacy data in children.
• In February 2024, the SANOIN study, supported by P&G Health, revealed that Sangobion (ferrous gluconate + multivitamins & minerals) significantly increased Hemoglobin (Hb) levels in 14 days, provided symptom relief in 30 days, and improved quality of life in women with Iron Deficiency Anemia (IDA). Anemia remains a major public health concern, especially in Southeast Asia, where up to 1 in 4 people are affected.
• In February 2024, Emcure Pharmaceuticals launched the ‘Unmask Anemia’ initiative to raise awareness about iron deficiency anemia among women in India. The initiative aims to improve early detection and treatment through self-assessment tools, promoting better health outcomes, the company stated.
• In October 2023, biotech firm Sanguina, Inc. received U.S. FDA clearance for AnemoCheck Home, the first and only FDA-approved home hemoglobin test kit. Designed for individuals with anemia (iron deficiency, vitamin B12, folate deficiency), sickle cell disease, and thalassemia, the in vitro diagnostic device enables at-home hemoglobin monitoring. Available by prescription, it ensures medical oversight.
• In June 2023, the U.S. FDA approved an expanded indication for ferric carboxymaltose injection (Injectafer, Daiichi Sankyo/American Regent) to treat iron deficiency in adults with NYHA class II/III heart failure. This marks the first FDA-approved intravenous iron therapy for heart failure patients, according to Dr. Ravi Tayi, Chief Medical Officer at American Regent.

Key Market Players

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

 Report Scope:

In this report, the Global Iron Deficiency Anemia Market   has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Iron Deficiency Anemia Market, By Therapy Type:

o   Oral Iron Therapy

o   Parenteral Iron Therapy

o   Red Blood Cell Transfusion

o   Others

• Iron Deficiency Anemia Market, By Therapy Areas:

o   Obstetrics and Gynecology

o   Oncology

o   Congestive Heart Failure (CHF)

o   Inflammatory Bowel Disease

o   Renal

o   Others

• Iron Deficiency Anemia Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Iron Deficiency Anemia Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Market.

Available Customizations:

Global Iron Deficiency Anemia Market   report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Iron Deficiency Anemia Market   is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com